Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) EPS (Weighted Average and Diluted) (2020 - 2024)

Solid Biosciences' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$1.02 for Q4 2024.

  • For Q4 2024, EPS (Weighted Average and Diluted) fell 2.0% year-over-year to -$1.02; the TTM value through Dec 2024 reached -$3.06, up 36.78%, while the annual FY2024 figure was -$3.06, 36.65% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2024 was -$1.02 at Solid Biosciences, down from -$0.79 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.17 in Q2 2021 and bottomed at -$8.97 in Q3 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$1.15 (2023), against an average of -$2.23.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 1858.82% in 2022 before it surged 88.29% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$6.17 in 2020, then skyrocketed by 60.13% to -$2.46 in 2021, then soared by 72.36% to -$0.68 in 2022, then crashed by 47.06% to -$1.0 in 2023, then decreased by 2.0% to -$1.02 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's EPS (Weighted Average and Diluted) are -$1.02 (Q4 2024), -$0.79 (Q3 2024), and -$0.61 (Q2 2024).